Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,001 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-bacterial Agents Clear all
Completed Phase 2Phase 3 Interventional Results available

Antibiotic Safety (SCAMP)

NCT01994993
View directory record Official record
Conditions
Complicated Intra Abdominal Infections
Interventions
ampicillin and metronidazole and gentamicin, ampicillin and gentamicin and clindamycin, gentamicin and Piperacillin- tazobactam, standard of care antibiotics and metronidazole, metronidazole, clindamycin, or piperacillin-tazobactam
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 120 Days
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

NCT03263273
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 6, 2026, 2:17 AM EDT
Completed No phase listed Observational

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

NCT02719769
View directory record Official record
Conditions
Bacteremia, Fungemia
Interventions
Not listed
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
4,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team

NCT05319561
View directory record Official record
Conditions
Common Infections, Urinary Tract Infections, Pneumonia
Interventions
Antibiotic Use Report
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

NCT00097773
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 6, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

NCT06321536
View directory record Official record
Conditions
Multi-Drug Resistant Organism Colonization
Interventions
Allogeneic Microbiota in Glycerol (9%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments

NCT01767064
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
Posted commitment letter
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery

NCT01912651
View directory record Official record
Conditions
Facial Defect
Interventions
cephalexin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Trial of MRSA Polymerase Chain Reaction for Pneumonia

NCT02660554
View directory record Official record
Conditions
Pneumonia, Methicillin-Resistant Staphylococcus Aureus
Interventions
Polymerase Chain Reaction (PCR)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)

NCT01454947
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
Clinical Decision Support (CDS): Accountable Justifications, Audit and Feedback: Peer Comparison, CDS Order Sets: Suggested Alternatives
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Anaheim, California • Bell, California • Commerce, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 6, 2026, 2:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Procalcitonin Protocol Use to Guide Antibiotic Therapy Duration in the Intensive Care Unit

NCT05756049
View directory record Official record
Conditions
Comparing Antibiotic Duration of Therapy
Interventions
compare antibiotic duration of therapy
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rifaximin for Chronic Immune Activation in People With HIV

NCT01866826
View directory record Official record
Conditions
HIV
Interventions
Rifaximin, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

NCT05033743
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Secnidazole 2 GM Oral Granules
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

NCT01802073
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Oral Vancomycin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 6, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

NCT00701636
View directory record Official record
Conditions
Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions
daptomycin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
19 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 6, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
12 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
North Little Rock, Arkansas • Stanford, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

NCT00136292
View directory record Official record
Conditions
Gram-positive Bacterial Infections
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Kansas City, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 6, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Acute Application of Antibiotic Powder in Open Fracture Wounds

NCT04872400
View directory record Official record
Conditions
Fractures, Open, Wounds and Injuries--Infections, Anti-Bacterial Agents, Fractures, Bone, Extremity Fracture Lower, Extremity Fractures Upper
Interventions
Vancomycin, Tobramycin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 6, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

NCT07406893
View directory record Official record
Conditions
Joint Arthroplasty, Shoulder, Cutibacterium Acnes, Prosthetic Joint Infection
Interventions
Prontosan Wound Gel
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 6, 2026, 2:17 AM EDT